Surface Oncology, GSK In License Agreement for Immunotherapy Program
2020年12月17日 - 10:01PM
Dow Jones News
By Michael Dabaie
Surface Oncology Inc. said it is in an agreement for
GlaxoSmithKline PLC to exclusively license worldwide development
and commercial rights to Surface Oncology's preclinical
immunotherapy program SRF813.
SRF813 is an IgG1 antibody targeting PVRIG, an inhibitory
protein expressed on natural killer cells and T cells.
Surface shares were up 7% to $10.70 premarket.
Under the deal, GSK will make an $85 million upfront payment.
Surface Oncology may receive up to an additional $730 million in
milestone payments and be eligible for royalties on net sales.
After the close of the GSK license agreement, with current cash
and cash equivalents, Surface Oncology said it projects cash runway
sufficient to fund operations through 2023.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 17, 2020 07:46 ET (12:46 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
過去 株価チャート
から 3 2024 まで 4 2024
Gsk (LSE:GSK)
過去 株価チャート
から 4 2023 まで 4 2024
